Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040).

Saved in:
Bibliographic Details
Title: Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040).
Authors: Sangro B; Liver Unit, Clinica Universidad de Navarra-IDISNA and CIBEREHD, Pamplona, Spain., Yau T; University of Hong Kong, Hong Kong Special Administrative Region, Pokfulam, China., El-Khoueiry AB; Keck School of Medicine, USC Norris Comprehensive Cancer Center, Los Angeles, California, USA., Kudo M; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan., Shen Y; Bristol Myers Squibb, Princeton, New Jersey, USA., Tschaika M; Bristol Myers Squibb, Princeton, New Jersey, USA., Roy A; Bristol Myers Squibb, Princeton, New Jersey, USA., Feng Y; Bristol Myers Squibb, Princeton, New Jersey, USA., Gao L; Bristol Myers Squibb, Princeton, New Jersey, USA., Aras U; Bristol Myers Squibb, Princeton, New Jersey, USA.
Source: Clinical and translational science [Clin Transl Sci] 2023 Aug; Vol. 16 (8), pp. 1445-1457. Date of Electronic Publication: 2023 May 30.
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1752-8062
DOI:10.1111/cts.13544